[HTML][HTML] Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2, 2 million individuals
Abstract Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination
for girls at 12–13 years of age to protect against virus types causing cervical cancer …
for girls at 12–13 years of age to protect against virus types causing cervical cancer …
Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2, 2 million individuals
S Nygård, M Nygård, M Orumaa, BT Hansen - Vaccine, 2023 - pubmed.ncbi.nlm.nih.gov
Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination for girls
at 12-13 years of age to protect against virus types causing cervical cancer, HPV16/18, and …
at 12-13 years of age to protect against virus types causing cervical cancer, HPV16/18, and …
Quadrivalent HPV vaccine effectiveness against anogenital warts: a registry-based study of 2, 2 million individuals.
S Nygård, M Nygård, M Orumaa, BT Hansen - 2023 - cabidigitallibrary.org
Abstract Background: In 2009, Norway initiated routine quadrivalent HPV (qHPV)
vaccination for girls at 12-13 years of age to protect against virus types causing cervical …
vaccination for girls at 12-13 years of age to protect against virus types causing cervical …
[PDF][PDF] Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2, 2 million individuals
S Nygård, M Nygård, M Orumaa, BLTT Hansen - 2023 - fhi.brage.unit.no
ABSTRACT Background: In 2009, Norway initiated routine quadrivalent HPV (qHPV)
vaccination for girls at 12–13 years of age to protect against virus types causing cervical …
vaccination for girls at 12–13 years of age to protect against virus types causing cervical …
[PDF][PDF] Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2, 2 million individuals
S Nygård, M Nygård, M Orumaa, BT Hansen - researchgate.net
ABSTRACT Background: In 2009, Norway initiated routine quadrivalent HPV (qHPV)
vaccination for girls at 12–13 years of age to protect against virus types causing cervical …
vaccination for girls at 12–13 years of age to protect against virus types causing cervical …
Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2, 2 million individuals.
S Nygård, M Nygård, M Orumaa, BT Hansen - Vaccine, 2023 - europepmc.org
Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination for girls
at 12-13 years of age to protect against virus types causing cervical cancer, HPV16/18, and …
at 12-13 years of age to protect against virus types causing cervical cancer, HPV16/18, and …